Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
June 11th 2015Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.